962
0
Loading version...
🔄 Update App
🔍 Check for Updates
Test Notification
🔔 Enable Notifications
📰 Fetch NHK News
🚀 Fetch TechCrunch News
🧪 Experiment
📰 Wordlist List
📚 Reading List
🎤 Speaking List
📊 Statistics
💻 Software Statistics
Push Admin
Edit Reading
Back to List
Basic Information
Title
Please enter a title.
URL
Please enter a valid URL.
Date
カテゴリID
画像ファイル名
単語数（空欄の場合は本文から自動計算）
空欄の場合は本文から自動計算されます。本文が空欄の場合は既存の値が保持されます。
統計情報
現在の単語数:
143語
読了回数:
0回
作成日:
2023/08/02 07:33
更新日:
2025/12/09 01:24
本文
本文
NHK has learned that an expert panel at Japan's health ministry will decide later this month whether to approve a new drug to treat Alzheimer's disease. If approved, it will pave the way for the production and sale in Japan of the first drug that removes the abnormal protein that causes the neurodegenerative disease. Sources told NHK that the ministry will convene the panel on August 21 to discuss whether to approve lecanemab, jointly developed by Japanese pharmaceutical firm Eisai and its US partner Biogen. The drug is designed to slow the progression of the disease by reducing the accumulation of amyloid beta in the brains of Alzheimer's patients. Eisai says the drug reduced the rate of cognitive decline in patients by 27 percent compared to a placebo in a clinical trial. The US Food and Drug Administration fully approved lecanemab in July.
メモ
メモ・感想
キャンセル
更新
Debug Info:
Saved State:
-
Redirected Flag:
-
Current URL:
-
Refresh
Close
Debug
Send Report
Send Report
Draw Arrow
Clear
Message:
Cancel
Send
